Asian Journal of Research in Pharmaceutical Sciences

Open Access Open Access  Restricted Access Subscription Access
Open Access Open Access Open Access  Restricted Access Restricted Access Subscription Access

Review on Idiopathic Pulmonary Fibrosis


Affiliations
1 Faculty of Pharmacy, Yashoda Technical Campus, Wadhe, Satara - 415015 India., India
2 Faculty of Pharmacy, Yashoda Technical Campus, Wadhe, Satara - 415015 India, India
     

   Subscribe/Renew Journal


Idiopathic pulmonary fibrosis (IPF) is an interstitial lung disease which is characterized by the chronic, progressive scarring of the lungs and by the usual interstitial pneumonia pathological hallmark. A key initiating factor is to damage alveolar epithelial cell was suggested by the current paradigms. Worldwide, with correlated high morbidity, mortality and economic burden increase in incidences of the disease. By exclusion of other causes of interstitial lung disease the diagnosis depends on a multidisciplinary team approach. Over recent years, for patients with IPF two novel antifibrotic treatment such as pirfenidone and nintedanib have been developed and providing the options for treatment, with several other agents in early clinical trials. To improve results for these patients in the future current efforts are directed at identifying key biomarkers that may direct more customized patient-centred healthcare.

Keywords

Idiopathic pulmonary fibrosis, Usual interstitial pneumonia, Interstitial lung disease, Pirfenidone, Nintedanib.
Subscription Login to verify subscription
User
Notifications
Font Size


  • Gross TJ, Hunninghake GW. Idiopathic pulmonary fibrosis. New England Journal of Medicine. 2001 Aug 16; 345(7):517-25.

  • Richeldi L, Collard HR, Jones MG. Idiopathic pulmonary fibrosis. The Lancet. 2017 May 13; 389(10082):1941-52.

  • Meltzer EB, Noble PW. Idiopathic pulmonary fibrosis. Orphanet Journal of Rare Diseases. 2008 Dec; 3(1):1-5.

  • Spagnolo P, Sverzellati N, Rossi G, Cavazza A, Tzouvelekis A, Crestani B, Vancheri C. Idiopathic Pulmonary Fibrosis: An update. Annals of Medicine. 2015 Jan 2; 47(1):15-27.

  • Barratt SL, Creamer A, Hayton C, Chaudhuri N. Idiopathic pulmonary fibrosis (IPF): an overview. Journal of Clinical Medicine. 2018 Aug; 7(8):201.

  • Ley B, Collard HR. Epidemiology of idiopathic pulmonary fibrosis. Clinical Epidemiology. 2013; 5:483.

  • Horowitz JC, Thannickal VJ. Idiopathic Pulmonary Fibrosis. Treatments in Respiratory Medicine. 2006 Oct; 5(5):325-42.

  • Ryu JH, Colby TV, Hartman TE. Idiopathic pulmonary fibrosis: current concepts. InMayo Clinic Proceedings 1998 Nov 1 (Vol. 73, No. 11, pp. 1085-1101). Elsevier.

  • Zaman T, Lee JS. Risk factors for the development of idiopathic pulmonary fibrosis: a review. Current Pulmonology Reports. 2018 Dec; 7(4):118-25.

  • Richeldi L, Du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, Cottin V, Flaherty KR, Hansell DM, Inoue Y, Kim DS. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. New England Journal of Medicine. 2014 May 29; 370(22): 2071-82.

  • Taniguchi H, Ebina M, Kondoh Y, Ogura T, Azuma A, Suga M, Taguchi Y, Takahashi H, Nakata K, Sato A, Takeuchi M. Pirfenidone in idiopathic pulmonary fibrosis. European Respiratory Journal. 2010 Apr 1; 35(4):821-9.

  • Richeldi L, Costabel U, Selman M, Kim DS, Hansell DM, Nicholson AG, Brown KK, Flaherty KR, Noble PW, Raghu G, Brun M. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. New England Journal of Medicine. 2011 Sep 22; 365(12):1079-87.

  • Somogyi V, Chaudhuri N, Torrisi SE, Kahn N, Müller V, Kreuter M. The therapy of idiopathic pulmonary fibrosis: what is next?. European Respiratory Review. 2019 Sep 30; 28(153).

  • Park J, Kim DS, Shim TS, Lim CM, Koh Y, Lee SD, Kim WS, Kim WD, Lee JS, Song KS. Lung cancer in patients with idiopathic pulmonary fibrosis. European Respiratory Journal. 2001 Jun 1; 17(6):1216-9.

  • Kim DS, Park JH, Park BK, Lee JS, Nicholson AG, Colby T. Acute exacerbation of idiopathic pulmonary fibrosis: frequency and clinical features. European Respiratory Journal. 2006 Jan 1; 27(1):143-50.

  • Martinez FJ, Chisholm A, Collard HR, Flaherty KR, Myers J, Raghu G, Walsh SL, White ES, Richeldi L. The diagnosis of idiopathic pulmonary fibrosis: current and future approaches. The Lancet Respiratory Medicine. 2017 Jan 1; 5(1):61-71.

  • Woodcock HV, Maher TM. The treatment of idiopathic pulmonary fibrosis. F1000 Prime Reports. 2014; 6.

  • Mason DP, Brizzio ME, Alster JM, McNeill AM, Murthy SC, Budev MM, Mehta AC, Minai OA, Pettersson GB, Blackstone EH. Lung transplantation for idiopathic pulmonary fibrosis. The Annals of Thoracic Surgery. 2007 Oct 1; 84(4):1121-8


Abstract Views: 111

PDF Views: 0




  • Review on Idiopathic Pulmonary Fibrosis

Abstract Views: 111  |  PDF Views: 0

Authors

Sonam Kuchekar
Faculty of Pharmacy, Yashoda Technical Campus, Wadhe, Satara - 415015 India., India
Rupali Jadhav
Faculty of Pharmacy, Yashoda Technical Campus, Wadhe, Satara - 415015 India, India

Abstract


Idiopathic pulmonary fibrosis (IPF) is an interstitial lung disease which is characterized by the chronic, progressive scarring of the lungs and by the usual interstitial pneumonia pathological hallmark. A key initiating factor is to damage alveolar epithelial cell was suggested by the current paradigms. Worldwide, with correlated high morbidity, mortality and economic burden increase in incidences of the disease. By exclusion of other causes of interstitial lung disease the diagnosis depends on a multidisciplinary team approach. Over recent years, for patients with IPF two novel antifibrotic treatment such as pirfenidone and nintedanib have been developed and providing the options for treatment, with several other agents in early clinical trials. To improve results for these patients in the future current efforts are directed at identifying key biomarkers that may direct more customized patient-centred healthcare.

Keywords


Idiopathic pulmonary fibrosis, Usual interstitial pneumonia, Interstitial lung disease, Pirfenidone, Nintedanib.

References